{"product_id":"endonovo-swot-analysis","title":"Endonovo Therapeutics SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete SWOT Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eEndonovo Therapeutics possesses unique strengths in its innovative regenerative medicine technologies, but faces challenges in market adoption and regulatory hurdles. Understanding these dynamics is crucial for any investor or strategist looking at the company's future. \u003c\/p\u003e\n\u003cp\u003eWant the full story behind Endonovo Therapeutics' strengths, risks, and growth drivers? Purchase the complete SWOT analysis to gain access to a professionally written, fully editable report designed to support planning, pitches, and research.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Non-Invasive Electroceutical Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEndonovo Therapeutics' key strength lies in its proprietary non-invasive electroceutical technology, exemplified by the SofPulse® device. This innovative platform is engineered to alleviate pain, reduce inflammation and edema, and notably boost microcirculation, thereby accelerating tissue repair.\u003c\/p\u003e\n\u003cp\u003eThis technology presents a compelling non-pharmacological and non-invasive treatment option, a significant differentiator in a healthcare landscape actively pursuing alternatives to conventional drug therapies, especially for pain management and wound healing.\u003c\/p\u003e\n\u003cp\u003eThe company's distinctive method of leveraging bioelectricity for therapeutic purposes sets it apart from competitors, offering a unique value proposition in the medical device market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA Clearance and CE Mark for Key Applications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEndonovo Therapeutics' SofPulse® device boasts significant regulatory achievements, including FDA clearance for pain and post-surgical edema palliation. This clearance is a critical step, paving the way for broader market access and adoption in the United States.\u003c\/p\u003e\n\u003cp\u003eFurthermore, the device has secured a CE Mark, expanding its commercial reach into European markets for wound healing, pain management, and post-surgical edema. These international approvals underscore the device's versatility and potential across different therapeutic areas.\u003c\/p\u003e\n\u003cp\u003eThe presence of CMS National Coverage for chronic wounds is a substantial advantage, directly translating to reimbursement potential. This coverage is vital for driving commercialization, as it signals a clear pathway for healthcare providers to be compensated for using SofPulse®, particularly in the significant chronic wound market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroad Therapeutic Pipeline and Platform Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEndonovo's strength lies in its broad therapeutic pipeline, which extends beyond its SofPulse® device. This pipeline includes clinical-stage Electroceutical Therapies aimed at a range of conditions, from cardiovascular diseases and central nervous system disorders like concussions and multiple sclerosis, to potential treatments for ARDS and cytokine storm.\u003c\/p\u003e\n\u003cp\u003eThe company's Cytotronics™ platform is a significant asset, offering a versatile method for cell expansion and manipulation. This technology is crucial for advancing tissue engineering and cell therapies, showcasing Endonovo's commitment to innovative solutions across multiple medical fields.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePositive Clinical Study Results and Veteran's Administration Adoption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEndonovo Therapeutics' SofPulse® device has shown promising results in clinical studies, notably in reducing postoperative pain and the need for narcotic pain medication. These studies also indicated a decrease in the average length of hospital stays for patients treated with SofPulse®.\u003c\/p\u003e\n\u003cp\u003eThe adoption by the Michael DeBakey VA Medical Center since 2019 serves as a significant validation. This ongoing use by surgeons there underscores the device's practical efficacy in a real-world clinical setting.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eClinical Efficacy:\u003c\/strong\u003e SofPulse® demonstrably reduces postoperative pain and narcotic consumption.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReduced Hospital Stays:\u003c\/strong\u003e Studies show a shorter length of stay for patients using the device.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eVA Adoption:\u003c\/strong\u003e Consistent use at Michael DeBakey VA Medical Center since 2019.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eExpansion Plans:\u003c\/strong\u003e Scheduled integration into broader VA and DoD medical systems.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Business Restructuring and Market Focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEndonovo Therapeutics has strategically repositioned itself by divesting its medical division and associated intellectual property to SofPulse, Inc. This significant transaction, valued at a minimum of $50 million, allows Endonovo to concentrate its efforts on high-growth areas.\u003c\/p\u003e\n\u003cp\u003eThe company retains crucial rights to develop non-medical human Pulsed Electromagnetic Field (PEMF) therapy intellectual property and to operate within the wellness markets. This focused strategy is designed to capitalize on emerging opportunities, particularly in the expanding U.S. PEMF therapy device wellness sector.\u003c\/p\u003e\n\u003cp\u003eThis restructuring enhances Endonovo's market focus, enabling a more streamlined approach to innovation and resource allocation. The company's comprehensive telehealth division also remains a key component of its future strategy.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Divestment:\u003c\/strong\u003e Sale of medical division and IP to SofPulse, Inc. for at least $50 million.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRetained Rights:\u003c\/strong\u003e Ownership of non-medical human PEMF IP and wellness market development.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Focus:\u003c\/strong\u003e Specialization in the growing U.S. PEMF therapy device wellness market.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOperational Strength:\u003c\/strong\u003e Continued operation of a comprehensive telehealth division.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovative Electroceutical Tech: Pain Relief, Reimbursement, \u0026amp; Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEndonovo's proprietary electroceutical technology, particularly the SofPulse® device, stands as a core strength, offering a non-invasive, non-pharmacological approach to pain management, inflammation reduction, and accelerated tissue repair. This unique technology is further bolstered by significant regulatory milestones, including FDA clearance for pain and edema, and a CE Mark for European markets, indicating broad applicability and market access potential.\u003c\/p\u003e\n\u003cp\u003eThe company's strategic divestment of its medical division to SofPulse, Inc. for a minimum of $50 million sharpens its focus on the burgeoning U.S. PEMF therapy device wellness market, while retaining valuable intellectual property and its telehealth division.\u003c\/p\u003e\n\u003cp\u003eFurthermore, the presence of CMS National Coverage for chronic wounds provides a critical pathway for reimbursement, directly impacting commercial viability in a substantial market segment.\u003c\/p\u003e\n\u003cp\u003eEndonovo's clinical evidence, showing reduced postoperative pain and narcotic use, alongside shorter hospital stays, is a powerful testament to SofPulse®'s efficacy, further validated by its ongoing adoption at the Michael DeBakey VA Medical Center since 2019.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a strategic overview of Endonovo Therapeutics’s internal and external business factors, highlighting its potential for growth through innovative technologies and market expansion, while also acknowledging challenges in regulatory approval and market penetration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eEndonovo Therapeutics' SWOT analysis offers a clear roadmap for navigating the competitive landscape, highlighting its strengths in innovative pain relief technology and opportunities for market expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Revenue and Market Capitalization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEndonovo Therapeutics reported limited trailing 12-month revenue of $0.00 as of March 31, 2025.  This signifies a very early stage of commercialization or a focus on research and development rather than immediate product sales.  Its market capitalization of approximately $30.5 million also underscores a smaller operational scale and potentially constrained financial resources when compared to established players in the biotechnology sector.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHistory of Delayed Filings and Unpredictable Financials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEndonovo Therapeutics has a notable history of delayed filings with the Securities and Exchange Commission (SEC), impacting its quarterly and annual reports. This pattern of late submissions, as seen in past filings, creates significant uncertainty for investors trying to assess the company's financial health.\u003c\/p\u003e\n\u003cp\u003eThe inability to reliably forecast Endonovo's future earnings is a direct consequence of this inconsistent financial reporting. With insufficient historical data readily available and a general lack of analyst coverage or forecasts, it's challenging to build a predictable financial model for the company.\u003c\/p\u003e\n\u003cp\u003eThis lack of transparency and predictability in financial disclosures can be a major deterrent for potential investors. It erodes confidence and makes it difficult for stakeholders to make informed decisions, potentially impacting Endonovo's ability to attract capital and support its growth initiatives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Stock Price Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEndonovo Therapeutics has faced considerable stock price swings, a common trait in the biotech industry. However, a notable increase in its weekly volatility, climbing from 78% to 110% over the past year, highlights a particularly elevated risk for investors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntense Competition in Bioelectronic and Regenerative Medicine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEndonovo Therapeutics faces a significant challenge due to the sheer number of players in its chosen fields. The bioelectronic and regenerative medicine sectors are crowded, with reports indicating over 100 active competitors vying for attention and market share. This intense competition necessitates substantial and continuous investment in research and development to stay ahead, as well as robust marketing efforts to differentiate its offerings.\u003c\/p\u003e\n\u003cp\u003eThe crowded nature of the market makes it difficult for Endonovo to carve out a substantial niche. Companies must not only innovate but also effectively communicate the value of their therapies to healthcare providers and patients. This requires a deep understanding of market dynamics and a willingness to allocate significant resources to capture and maintain market position.\u003c\/p\u003e\n\u003cp\u003eKey challenges stemming from this intense competition include:\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eHigh R\u0026amp;D Expenditure:\u003c\/strong\u003e Sustaining innovation in a rapidly evolving field demands continuous and significant investment in research and development to create novel therapies and devices.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarketing and Sales Hurdles:\u003c\/strong\u003e Differentiating products and building brand recognition among a large number of competitors requires substantial marketing and sales efforts, increasing operational costs.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePricing Pressures:\u003c\/strong\u003e A saturated market can lead to pricing pressures as competitors vie for customer adoption, potentially impacting profit margins for Endonovo.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTalent Acquisition:\u003c\/strong\u003e Attracting and retaining top scientific and technical talent is crucial but becomes more challenging in a competitive landscape where multiple companies are seeking the same expertise.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependency on Spin-off Success and Future Funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEndonovo Therapeutics' future trajectory is significantly tied to the performance of SofPulse, Inc., following their asset purchase agreement and subsequent spin-off.  The success of SofPulse's development and commercialization efforts is therefore a critical factor for Endonovo's continued growth and value realization.\u003c\/p\u003e\n\u003cp\u003eSofPulse, Inc. is actively seeking additional capital through a capital raise. This move underscores the company's need for funding to advance its development pipeline and pursue its goal of an Initial Public Offering (IPO) and listing on the NASDAQ exchange.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eReliance on SofPulse:\u003c\/strong\u003e Endonovo's strategic shift positions its future success heavily on SofPulse's ability to bring its technology to market.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCapital Needs:\u003c\/strong\u003e SofPulse's ongoing capital raise highlights the significant investment required for product development, regulatory approvals, and market entry.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIPO Aspirations:\u003c\/strong\u003e The potential NASDAQ listing for SofPulse represents a key liquidity event and valuation milestone that Endonovo is indirectly dependent upon.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZero Revenue, SEC Delays Cloud Future for Company\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEndonovo Therapeutics faces significant hurdles due to its lack of current revenue, reporting $0.00 in trailing twelve-month revenue as of March 31, 2025. This, coupled with a market capitalization of approximately $30.5 million, indicates a nascent stage of development and potentially limited financial resources. The company's history of delayed SEC filings further exacerbates investor uncertainty, making financial forecasting and informed decision-making difficult.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eEndonovo Therapeutics SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. It provides a comprehensive overview of Endonovo Therapeutics' Strengths, Weaknesses, Opportunities, and Threats, ready for your strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55610708296057,"sku":"endonovo-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/endonovo-swot-analysis.png?v=1754744503","url":"https:\/\/growthsharematrix.com\/products\/endonovo-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}